Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Interest & Investment Income (2020 - 2024)

Immuneering has reported Interest & Investment Income over the past 5 years, most recently at $415240.0 for Q4 2024.

  • Quarterly results put Interest & Investment Income at $415240.0 for Q4 2024, down 44.94% from a year ago — trailing twelve months through Dec 2024 was $2.6 million (down 28.1% YoY), and the annual figure for FY2025 was $3.0 million, up 17.2%.
  • Interest & Investment Income for Q4 2024 was $415240.0 at Immuneering, down from $547072.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for IMRX hit a ceiling of $1.2 million in Q2 2023 and a floor of $518.0 in Q4 2020.
  • Median Interest & Investment Income over the past 5 years was $222985.0 (2022), compared with a mean of $388883.7.
  • Biggest five-year swings in Interest & Investment Income: soared 27483.98% in 2021 and later plummeted 44.94% in 2024.
  • Immuneering's Interest & Investment Income stood at $518.0 in 2020, then soared by 27483.98% to $142885.0 in 2021, then soared by 261.25% to $516168.0 in 2022, then soared by 46.1% to $754144.0 in 2023, then plummeted by 44.94% to $415240.0 in 2024.
  • The last three reported values for Interest & Investment Income were $415240.0 (Q4 2024), $547072.0 (Q3 2024), and $826104.0 (Q2 2024) per Business Quant data.